CN Patent

CN118994204A — Wrn抑制剂及其用途

Assigned to Xuanzhu Biopharmaceutical Co Ltd · Expires 2024-11-22 · 1y expired

What this patent protects

本发明涉及医药技术领域，具体涉及WRN抑制剂、其药学上可接受的盐、其酯或其立体异构体，含有所述化合物、其药学上可接受的盐、其酯或其立体异构体的药物组合物及制剂，制备所述化合物、其药学上可接受的盐、其酯或其立体异构体的方法，以及所述化合物、其药学上可接受的盐、其酯或其立体异构体在制备治疗和/或预防由WRN介导的疾病及相关疾病的药物中的用途。

USPTO Abstract

本发明涉及医药技术领域，具体涉及WRN抑制剂、其药学上可接受的盐、其酯或其立体异构体，含有所述化合物、其药学上可接受的盐、其酯或其立体异构体的药物组合物及制剂，制备所述化合物、其药学上可接受的盐、其酯或其立体异构体的方法，以及所述化合物、其药学上可接受的盐、其酯或其立体异构体在制备治疗和/或预防由WRN介导的疾病及相关疾病的药物中的用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN118994204A
Jurisdiction
CN
Classification
—
Expires
2024-11-22
Drug substance claim
No
Drug product claim
No
Assignee
Xuanzhu Biopharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.